No. S 190
Poisons Act
(Chapter 234)
Poisons Act (Amendment of Schedule) Notification 2004
In exercise of the powers conferred by section 3(2) of the Poisons Act, Mr Khaw Boon Wan, Senior Minister of State, Ministry of Finance, charged with the responsibility of the Minister for Health, hereby makes the following Notification:
Citation and commencement
1.    This Notification may be cited as the Poisons Act (Amendment of Schedule) Notification 2004 and shall come into operation on 14th April 2004.
Amendment of Schedule
2.  The Schedule to the Poisons Act is amended —
(a)by inserting, immediately below the item “Acyclovir”, the following item:
Adalimumab”;
(b)by inserting, immediately below the item “Adapalene”, the following item:
Adefovir dipivoxil”;
(c)by inserting, immediately below the item “Aldosterone”, the following item:
Alemtuzumab”;
(d)by inserting, immediately below the item “Amylocaine; its salts”, the following item:
Anagrelide; its salts”;
(e)by inserting, immediately below the item “Apramycin; its salts”, the following item:
Aprepitant”;
(f)by inserting, immediately below the item “Aprotinin”, the following item:
Aripiprazole”;
(g)by inserting, immediately below the item “Astemizole”, the following item:
Atazanavir; its salts”;
(h)by inserting, immediately below the item “Bifonazole”, the following item:
Bimatoprost”;
(i)by inserting, immediately below the item “Boric acid; sodium borate”, the following item:
Bosentan; its salts”;
(j)by inserting, immediately below the item “Calcium carbimide”, the following item:
Calcium dobesilate”;
(k)by inserting, immediately below the item “Carbenoxolone; its salts”, the following item:
Carbetocin”;
(l)by deleting the item “Chlorpheniramine; its salts” and substituting the following item:
Chlorpheniramine; its salts; its isomers; their salts”;
(m)by deleting the item “Citalopram; its salts” and substituting the following items:
Citalopram; its salts; its isomers; their salts Citicoline”;
(n)by inserting, immediately below the item “Clemizole; its salts”, the following item:
Clenbuterol”;
(o)by inserting, immediately below the item “Clostebol; its salts”, the following item:
Clostridiopeptidase A”;
(p)by inserting, immediately below the item “Dexfenfluramine; its salts”, the following item:
Dexrazoxane”;
(q)by inserting, immediately below the item “Drotebanol”, the following items:
Drotrecogin alpha Dutasteride”;
(r)by inserting, immediately below the item “Epithiazide”, the following item:
Eplerenone; its salts”;
(s)by inserting, immediately below the item “Eptifibatide”, the following item:
Erdosteine; its salts”;
(t)by inserting, immediately below the item “Ergotoxine; its salts”, the following item:
Ertapenem; its salts”;
(u)by inserting, immediately below the item “Etryptamine; its salts; its esters; their salts”, the following item:
Ezetimibe”;
(v)by inserting, immediately below the item “Gatifloxacin; its salts; its isomers; its esters; their salts”, the following item:
Gefitinib”;
(w)by inserting, immediately below the item “Glyceryl trinitrate”, the following item:
Glycopyrrolate”;
(x)by inserting, immediately below the item “Ifosfamide”, the following item:
Iloprost; its salts; its esters; their salts”;
(y)by inserting, immediately below the item “Indomethacin; its salts”, the following item:
Infliximab”;
(z)by inserting, immediately below the item “Isradipine”, the following item:
Itopride; its salts”;
(za)by deleting the item “Ketoprofen” and substituting the following item:
Ketoprofen; its isomers”;
(zb)by inserting, immediately below the item “Lacidipine”, the following item:
Lafutidine”;
(zc)by deleting the item “Loratadine” and substituting the following item:
Loratadine; its isomers”;
(zd)by inserting, immediately below the item “Losartan; its salts”, the following item:
Loteprednol; its salts”;
(ze)by inserting, immediately below the item “Luteinising hormones”, the following item:
Lutropin alpha”;
(zf)by inserting, immediately below the item “Melphalan”, the following item:
Memantine; its salts”;
(zg)by inserting, immediately below the item “Moxalactam; its salts”, the following item:
Moxifloxacin; its salts”;
(zh)by inserting, immediately below the item “Nadolol”, the following item:
Nadroparin; its salts”;
(zi)by inserting, immediately below the item “Nordazepam”, the following item:
Norelgestromin”;
(zj)by inserting, immediately below the item “Paramethoxyamphetamine”, the following item:
Parecoxib; its salts”;
(zk)by inserting, immediately below the item “Pilocarpine; its salts”, the following item:
Pimecrolimus”;
(zl)by inserting, immediately below the item “Pinazepam”, the following item:
Pioglitazone; its salts”;
(zm)by inserting, immediately below the item “Propiram; its salts”, the following item:
Propiverine; its salts”;
(zn)by inserting, immediately below the item “13-cis Retinoic acid”, the following item:
Reviparin; its salts”;
(zo)by inserting, immediately below the item “Rosoxacin”, the following item:
Rosuvastatin”;
(zp)by inserting, immediately below the item “Secbutobarbitone; its salts”, the following item:
Secnidazole”;
(zq)by inserting, immediately below the item “Tacrolimus; its salts”, the following item:
Tadalafil; its salts”;
(zr)by inserting, immediately below the item “Tamoxifen; its salts”, the following item:
Tazarotene”;
(zs)by inserting, immediately below the item “Tegafur”, the following item:
Tegaserod; its salts”;
(zt)by inserting, immediately below the item “Terfenadine”, the following item:
Teriparatide”;
(zu)by inserting, immediately below the item “Trifluridine; its salts; its esters; their salts”, the following item:
Triflusal; its salts; its esters; their salts”;
(zv)by inserting, immediately below the item “Trimebutine; its salts”, the following item:
Trimegestone”;
(zw)by inserting, immediately below the item “Tropisetron; its salts”, the following item:
Trospium; its salts”;
(zx)by inserting, immediately below the item “Tyrothricin; its salts; its esters and their salts”, the following item:
Unoprostone; its salts; its esters and their salts”;
(zy)by deleting the item “Urea, when contained in preparations intended for treatment of human ailments and containing more than 10% of urea” and substituting the following item:
Urea, when contained in preparations intended for human consumption, except external preparations containing not more than 10% of urea”;
(zz)by inserting, immediately below the item “Valaciclovir; its salts”, the following items:
Valdecoxib Valganciclovir; its salts”;
(zza)by inserting, immediately below the item “Vancomycin; its salts; its esters; their salts”, the following item:
Vardenafil; its salts; its active derivatives”;
(zzb)by inserting, immediately below the item “Virginiamycin; its salts; its esters; their salts”, the following item:
Voriconazole”; and
(zzc)by inserting, immediately below the item “Ziprasidone; its salts”, the following item:
Zofenopril; its salts”.

Made this 2nd day of April 2004.

MOSES LEE
Permanent Secretary,
Ministry of Health,
Singapore.
[CPA (PER): 78:01 Vol. 5; AG/LEG/SL/234/2002/1 Vol.1]